Welcome!
Comprehensive Resistance Prediction for Tuberculosis: an International Consortium is a world-wide collaboration between tuberculosis (TB) research institutions all over the world to achieve better, faster and more targeted treatment of multidrug-resistant TB via genetic resistance prediction.
Twitter: @CRyPTICproject
About the project
CRyPTIC’s aim is to help improve control of tuberculosis and facilitate WHO’s End TB Strategy by better, faster and more targeted treatment of drug-resistant tuberculosis via genetic resistance prediction, paving the way towards universal drug susceptibility testing (DST).
Our ultimate goal is to achieve sufficiently accurate genetic prediction of resistance to most anti-tuberculosis drugs, so that whole genome sequencing can replace culture-based DST for TB. This will enable rapid-turnaround near-to-patient assays to revolutionise MDR-TB identification and management. This project is funded by MRC Newton Fund, Wellcome Trust, and Bill & Melinda Gates Foundation.
Updates
New publication: Structure of MmpL3 protein
Oliver Adams, as part of his DPhil studies in Simon Newstead's group at the University of Oxford, has resolved the structure of MmpL3 which is the only essential member of the mmpL family of genes.
WHO tuberculosis mutation catalogue released
Last Friday 25 June 2021, the World Health Organization released their first report containing a catalogue of mutations in Mycobacterium tuberculosis and their association with drug resistance. The CRyPTIC project shared its large and comprehensive
Internal project seminars in June 2021
The analysis group will be presenting five consecutive seminars starting on Wed 9 June at 1500 BST (1400 GMT). Each seminar will focus on one of the primary publications to come from the CRyPTIC project.